Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial

被引:362
|
作者
Caraceni, Paolo [1 ,2 ]
Riggio, Oliviero [3 ]
Angeli, Paolo [4 ]
Alessandria, Carlo [5 ]
Neri, Sergio [6 ]
Foschi, Francesco G. [7 ]
Levantesi, Fabio [8 ]
Airoldi, Aldo [9 ]
Boccia, Sergio [10 ]
Svegliati-Baroni, Gianluca [11 ]
Fagiuoli, Stefano [12 ]
Romanelli, Roberto G. [13 ]
Cozzolongo, Raffaele [14 ]
Di Marco, Vito [15 ]
Sangiovanni, Vincenzo [16 ]
Morisco, Filomena [17 ]
Toniutto, Pierluigi [18 ]
Tortora, Annalisa [19 ]
De Marco, Rosanna [20 ]
Angelico, Mario [21 ]
Cacciola, Irene [22 ]
Elia, Gianfranco [23 ]
Federico, Alessandro [24 ]
Massironi, Sara [25 ,26 ]
Guarisco, Riccardo [27 ]
Galioto, Alessandra [28 ]
Ballardini, Giorgio [29 ]
Rendina, Maria [30 ]
Nardelli, Silvia [3 ]
Piano, Salvatore [4 ]
Elia, Chiara [5 ]
Prestianni, Loredana [6 ]
Cappa, Federica Mirici [7 ]
Cesarini, Lucia [9 ]
Simone, Loredana [10 ]
Pasquale, Chiara [3 ]
Cavallin, Marta [4 ]
Andrealli, Alida [5 ]
Fidone, Federica [6 ]
Ruggeri, Matteo [31 ]
Roncadori, Andrea [32 ]
Baldassarre, Maurizio [1 ,2 ]
Tufoni, Manuel [1 ,2 ]
Zaccherini, Giacomo [1 ,2 ]
Bernardi, Mauro [1 ,2 ]
机构
[1] Univ Bologna, Dept Med & Surg Sci, Bologna, Italy
[2] Univ Bologna, Ctr Appl Biomed Res, Bologna, Italy
[3] Sapienza Univ Rome, Dept Clin Med, Rome, Italy
[4] Univ Padua, Dept Med, Unit Internal Med & Hepatol, Padua, Italy
[5] Univ Turin, Div Gastroenterol & Hepatol, Citta Salute & Sci Hosp, Turin, Italy
[6] Univ Catania, Dept Clin & Expt Med, Catania, Italy
[7] Hosp Faenza, Internal Med, Azienda Unita Sanit Locale Romagna, Faenza, Italy
[8] Hosp Bentivoglio, AUSL Bologna, Internal Med, Bologna, Italy
[9] Osped Niguarda Ca Granda, Dept Gastroenterol & Hepatol, Liver Unit, Milan, Italy
[10] Univ Hosp, Gastroenterol Unit, Ferrara, Italy
[11] Polytech Univ Marche, Dept Gastroenterol, Ancona, Italy
[12] Papa Giovanni XXIII Hosp, Gastroenterol & Transplant Hepatol, Bergamo, Italy
[13] Univ Florence, Dept Expt & Clin Med, Florence, Italy
[14] Natl Inst Gastroenterol S De Bellis, Div Gastroenterol, Bari, Italy
[15] Univ Palermo, Biomed Dept Internal & Specialist Med, Unit Gastroenterol & Hepatol, Palermo, Italy
[16] Cotugno Hosp Naples, Azienda Osped Rilievo Nazl Colli, Naples, Italy
[17] Federico II Univ Naples, Dept Clin Med & Surg, Gastroenterol Unit, Naples, Italy
[18] Univ Udine, Dept Med Area, Internal Med, Udine, Italy
[19] Catholic Univ, Gemelli Fdn, Gastroenterol, Rome, Italy
[20] Hosp Cosenza, Gastroenterol Unit, Cosenza, Italy
[21] Tor Vergata Univ, Liver Unit, Rome, Italy
[22] Univ Hosp Messina, Div Clin & Mol Hepatol, Messina, Italy
[23] Univ Hosp Parma, Infect Dis & Hepatol, Parma, Italy
[24] Univ Campania Luigi Vanvitelli, Dept Clin & Expt Internal Med, Naples, Italy
[25] Fdn Ist Ricovero, Gastroenterol & Endoscopy Unit, Milan, Italy
[26] Cura Carattere Sci Ca Granda Osped Maggiore Polic, Milan, Italy
[27] S Sebastiano Gen Hosp, Internal Med, Rome, Italy
[28] Hosp Dolo, Internal Med, Azienda Unita Locale Sociosanit Serenissima, Venice, Italy
[29] Hosp Rimini, AUSL Romagna, Rimini, Italy
[30] Univ Bari, Sect Gastroenterol, Dept Emergency & Organ Transplantat, Bari, Italy
[31] Catholic Univ, Grad Sch Hlth Econ & Management, Rome, Italy
[32] Cineca Interuniv Consortium, Bologna, Italy
来源
LANCET | 2018年 / 391卷 / 10138期
关键词
PERIPHERAL ARTERIAL VASODILATION; PLASMA EXPANDERS; NATURAL-HISTORY; LIVER-DISEASE; ASCITES; INFECTIONS; MANAGEMENT; SURVIVAL; IMPROVES; FAILURE;
D O I
10.1016/S0140-6736(18)30840-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Evidence is scarce on the efficacy of long-term human albumin (HA) administration in patients with decompensated cirrhosis. The human Albumin for the treatmeNt of aScites in patients With hEpatic ciRrhosis (ANSWER) study was designed to clarify this issue. Methods We did an investigator-initiated multicentre randomised, parallel, open-label, pragmatic trial in 33 academic and non-academic Italian hospitals. We randomly assigned patients with cirrhosis and uncomplicated ascites who were treated with anti-aldosteronic drugs (>= 200 mg/day) and furosemide (>= 25 mg/day) to receive either standard medical treatment (SMT) or SMT plus HA (40 g twice weekly for 2 weeks, and then 40 g weekly) for up to 18 months. The primary endpoint was 18-month mortality, evaluated as difference of events and analysis of survival time in patients included in the modified intention-to-treat and per-protocol populations. This study is registered with EudraCT, number 2008-000625-19, and ClinicalTrials. gov, number NCT01288794. Findings From April 2, 2011, to May 27, 2015, 440 patients were randomly assigned and 431 were included in the modified intention-to-treat analysis. 38 of 218 patients died in the SMT plus HA group and 46 of 213 in the SMT group. Overall 18-month survival was significantly higher in the SMT plus HA than in the SMT group (Kaplan-Meier estimates 77% vs 66%; p=0.028), resulting in a 38% reduction in the mortality hazard ratio (0.62 [95% CI 0.40-0.95]). 46 (22%) patients in the SMT group and 49 (22%) in the SMT plus HA group had grade 3-4 non-liver related adverse events. Interpretation In this trial, long-term HA administration prolongs overall survival and might act as a disease modifying treatment in patients with decompensated cirrhosis. (C) 2018 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2417 / 2429
页数:13
相关论文
共 50 条
  • [31] Association between vitamin D and uterine fibroids: a study protocol of an open-label, randomised controlled trial
    Sheng, Bo
    Song, Yizuo
    Liu, Yi
    Jiang, Chenchen
    Zhu, Xueqiong
    BMJ OPEN, 2020, 10 (11):
  • [32] Long-Term Efficacy and Safety of Stapokibart in Adults with Moderate-to-Severe Atopic Dermatitis: An Open-Label Extension, Nonrandomized Clinical Trial
    Zhao, Yan
    Li, Jing-Yi
    Yang, Bin
    Ding, Yang-Feng
    Wu, Li-Ming
    Zhang, Li-Tao
    Wang, Jin-Yan
    Lu, Qian-Jin
    Zhang, Chun-Lei
    Zhang, Fu-Ren
    Zhu, Xiao-Hong
    Li, Yu-Mei
    Tao, Xiao-Hua
    Diao, Qing-Chun
    Li, Lin-Feng
    Lu, Jian-Yun
    Man, Xiao-Yong
    Li, Fu-Qiu
    Xia, Xiu-Juan
    Song, Jiao-Ran
    Jia, Ying-Min
    Zhang, Li-Bo
    Chen, Bo
    Zhang, Jian-Zhong
    BIODRUGS, 2024, 38 (05) : 681 - 689
  • [33] Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial
    Takehara, Tetsuo
    Sakamoto, Naoya
    Nishiguchi, Shuhei
    Ikeda, Fusao
    Tatsumi, Tomohide
    Ueno, Yoshiyuki
    Yatsuhashi, Hiroshi
    Takikawa, Yasuhiro
    Kanda, Tatsuo
    Sakamoto, Minoru
    Tamori, Akihiro
    Mita, Eiji
    Chayama, Kazuaki
    Zhang, Gulan
    De-Oertel, Shampa
    Dvory-Sobol, Hadas
    Matsuda, Takuma
    Stamm, Luisa M.
    Brainard, Diana M.
    Tanaka, Yasuhito
    Kurosaki, Masayuki
    JOURNAL OF GASTROENTEROLOGY, 2019, 54 (01) : 87 - 95
  • [34] A Canadian multi-centre, open-label long-term study of Pegvisomant treatment in refractory acromegaly
    Ezzat, Shereen
    Gaspo, Rania
    Serri, Omar
    Ur, Ehud
    Chik, Constance L.
    CLINICAL AND INVESTIGATIVE MEDICINE, 2009, 32 (06): : E265 - E277
  • [35] Long-term safety and effectiveness of berotralstat for hereditary angioedema: The open-label APeX-S study
    Farkas, Henriette
    Stobiecki, Marcin
    Peter, Jonny
    Kinaciyan, Tamar
    Maurer, Marcus
    Aygoren-Pursun, Emel
    Kiani-Alikhan, Sorena
    Wu, Adrian
    Reshef, Avner
    Bygum, Anette
    Fain, Olivier
    Hagin, David
    Huissoon, Aarnoud
    Jesenak, Milos
    Lindsay, Karen
    Panovska, Vesna Grivcheva
    Steiner, Urs C.
    Zubrinich, Celia
    Best, Jessica M.
    Cornpropst, Melanie
    Dix, Daniel
    Dobo, Sylvia M.
    Iocca, Heather A.
    Desai, Bhavisha
    Murray, Sharon C.
    Nagy, Eniko
    Sheridan, William P.
    CLINICAL AND TRANSLATIONAL ALLERGY, 2021, 11 (04)
  • [36] Role of thoracic ultrasonography in pleurodesis pathways for malignant pleural effusions (SIMPLE): an open-label randomised controlled trial
    Psallidas, Ioannis
    Hassan, Maged
    Yousuf, Ahmed
    Duncan, Tracy
    Khan, Shahul Leyakathali
    Blyth, Kevin G.
    Evison, Matthew
    Corcoran, John P.
    Barnes, Simon
    Reddy, Raja
    Bonta, Peter, I
    Bhatnagar, Rahul
    Kagithala, Gayathri
    Dobson, Melissa
    Knight, Ruth
    Dutton, Susan J.
    Luengo-Fernandez, Ramon
    Hedley, Emma
    Piotrowska, Hania
    Brown, Louise
    Asa'ari, Kamal Abi Musa
    Mercer, Rachel M.
    Asciak, Rachelle
    Bedawi, Eihab O.
    Hallifax, Rob J.
    Slade, Mark
    Benamore, Rachel
    Edey, Anthony
    Miller, Robert F.
    Maskell, Nick A.
    Rahman, Najib M.
    LANCET RESPIRATORY MEDICINE, 2022, 10 (02): : 139 - 148
  • [37] Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial
    Judge, Daniel P.
    Gillmore, Julian D.
    Alexander, Kevin M.
    Ambardekar, Amrut V.
    Cappelli, Francesco
    Fontana, Marianna
    Garcia-Pavia, Pablo
    Grodin, Justin L.
    Grogan, Martha
    Hanna, Mazen
    Masri, Ahmad
    Nativi-Nicolau, Jose
    Obici, Laura
    Hvitfeldt Poulsen, Steen
    Sarswat, Nitasha
    Shah, Keyur
    Soman, Prem
    Lystig, Ted
    Cao, Xiaofan
    Wang, Kevin
    Pecoraro, Maria Lucia
    Tamby, Jean-Francois
    Katz, Leonid
    Sinha, Uma
    Fox, Jonathan C.
    Maurer, Mathew S.
    CIRCULATION, 2025, 151 (09) : 601 - 611
  • [38] Long-term treatment with teduglutide: a 48-week open-label single-center clinical trial in children with short bowel syndrome
    Lambe, Cecile
    Talbotec, Cecile
    Kapel, Nathalie
    Barbot-Trystram, Laurence
    Brabant, Severine
    Nader, Elie Abi
    Pigneur, Benedicte
    Payen, Elise
    Goulet, Olivier
    AMERICAN JOURNAL OF CLINICAL NUTRITION, 2023, 117 (06): : 1152 - 1163
  • [39] Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial
    Dehbi, Hakim-Moulay
    Mallick, Ujjal
    Wadsley, Jonathan
    Newbold, Kate
    Harmer, Clive
    Hackshaw, Allan
    LANCET DIABETES & ENDOCRINOLOGY, 2019, 7 (01): : 44 - 51
  • [40] Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial
    Biere, Surya S. A. Y.
    Henegouwen, Mark I. van Berge
    Maas, Kirsten W.
    Bonavina, Luigi
    Rosman, Camiel
    Roig Garcia, Josep
    Gisbertz, Suzanne S.
    Klinkenbijl, Jean H. G.
    Hollmann, Markus W.
    de lange, Elly S. M.
    Bonjer, H. Jaap
    van der Peet, Donald L.
    Cuesta, Miguel A.
    LANCET, 2012, 379 (9829): : 1887 - 1892